Filing Summary
Company: Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO). Filing: Form 8-K dated October 1, 2026. This is an event disclosure, not a periodic financial report.
Business Context and Trial Update
As of September 30, 2026, 330 patients had been randomized in the BACKBEAT Global Pivotal Trial of Atrioventricular Interval Modulation Therapy (AVIM Therapy), exceeding the previously announced enrollment target of 316. The trial evaluates AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension despite medication.
Patients were randomized at 81 sites across 13 countries. The FDA-approved protocol specifies 284 evaluable randomized subjects for the primary endpoint analysis; the 316-patient target accounts for potential loss to follow-up. The trial is being conducted with Medtronic, which is also the company’s strategic collaborator for potential commercialization in this patient population, subject to regulatory approval.
Financial Metrics and Comparisons
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no comparable-period financial results. It does not provide a clear estimate of the trial’s cost or financial impact.
Outlook, Risks, and Other Disclosures
Exceeding the enrollment target is a clinical-trial execution milestone; the filing does not report trial results or establish AVIM Therapy’s safety or efficacy. Commercialization remains subject to regulatory approval. No guidance, results timeline, or additional contingencies are stated in the supplied filing text.
The enrollment announcement appears under Item 8.01. The related press release is furnished under Item 7.01 and is not deemed filed for Exchange Act Section 18 purposes or incorporated by reference, as described in the filing.
Key Facts for Investors to Verify
- Whether the 284-subject primary endpoint analysis population is achieved and retained through follow-up.
- When the company expects to report trial results and what the primary endpoint findings show.
- Any subsequent regulatory decisions and the terms and progress of potential commercialization with Medtronic.
- Trial costs, cash runway, and other financial details, which are not provided in this 8-K.